Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: A pharmacogenetic approach

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 768-773

  De Pas, Tommaso M ^a   Toffalorio, Francesca ^a   Giovannetti, Elisa ^b   Radice, Davide ^c   Russo, Francesca ^d   Angeli, Ilaria ^e   Calamai, Giulia ^d   Spitaleri, Gianluca ^a   Catania, Chiara ^a   Noberasco, Cristina ^a   Milani, Alessandra ^a   Pelosi, Giuseppe ^a   Danesi, Romano ^b   De Braud, Filippo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Department of Epidemiology and Biostatistics ^*  (Italy)

^d ELI LILLY   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

dCK; Gemcitabine; Gene expression; hENT1; Pemetrexed

Indexed keywords

DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; BLEEDING; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 79953027121     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820d7818     Document Type: Article

References (25)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guide-line: update. American Society of Clinical Oncology. J Clin Oncol 2004;22:330-353. (Pubitemid 41095099)
2. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemother-apy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
4. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimi- dine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123. (Pubitemid 27138611)
5. Hanauske AR, Chen V, Paoletti P, et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-373. (Pubitemid 32816541)
6. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10:4276s-4280s. (Pubitemid 38812462)
7. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118. (Pubitemid 41002949)
8. Mey V, Giovannetti E, De Braud F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006; 95:289-297. (Pubitemid 44187589)
9. Tonkinson JL, Worzalla JF, Teng CH, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and anti-tumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671-3676. (Pubitemid 29381871)
10. Nagai S, Takenaka K, Sonobe M, et al. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines. Chemotherapy 2008;54:166-175. (Pubitemid 351929266)
11. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-1757. (Pubitemid 30220554)
12. Ma CX, Nair S, Thomas S, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-5937.
13. West HL, Wakelee HA, Perry MC, et al. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 2009;20: 850-856.
14. Russo F, Bearz A, Pampaloni G, et al. Pemetrexed single agent chemo-therapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 2008;8:216.
15. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previ-ously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-4212.
16. Sequist LV, Fidias P, Heist RS, et al. Brief report of biweekly pem-etrexed and gemcitabine in elderly patients with non-small cell lung cancer. J Thorac Oncol 2009;4:1170-1173.
17. Dudek AZ, Larson T, McCleod MJ, et al. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3:394-399. (Pubitemid 351489480)
18. Blakely LJ, Schwartzberg L, Keaton M, et al. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009;66:97-102.
19. Peacock NW, Spigel D, Hainsworth J, et al. A phase II trial of biweekly pemetrexed (P) and gemcitabine (G) in the first-line treatment (tx) of patients (pts) with advanced non-small cell lung cancer (NSCLC). Paper presented at the American Society ofClinical Oncology, Atlanta, GA, 2006. Available at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview= abst-detail- view&confID=40&abstractID=34809. Accessed January 24, 2011.
20. Spigel DR, Hainsworth JD, Barton JH, et al. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated ad-vanced non-small cell lung cancer. J Thorac Oncol 2010;5:841-845.
21. Dy GK, Suri A, Reid JM, et al. A phase IB study of the pharmacoki-netics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol 2005;55:522-530. (Pubitemid 40674627)
22. Blakely LJ, Schwartzberg L, Keaton M, et al. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009;66:97-102.
23. Smith MR. Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol 2008;15:415-421.
24. Lu YS, Lien HC, Yeh PY, et al. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer 2006;53:303-310.
25. Bergman AM, Pinedo HM, Peters GJ. Steroids affect collateral sensi-tivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 2001;416:19-24. (Pubitemid 32244430)